BRPI0507544A - combinação de agonistas de benzotiazol-2-ona beta-2 adrenoreceptores e corticosteróides para o tratamento de doenças respiratórias - Google Patents

combinação de agonistas de benzotiazol-2-ona beta-2 adrenoreceptores e corticosteróides para o tratamento de doenças respiratórias

Info

Publication number
BRPI0507544A
BRPI0507544A BRPI0507544-0A BRPI0507544A BRPI0507544A BR PI0507544 A BRPI0507544 A BR PI0507544A BR PI0507544 A BRPI0507544 A BR PI0507544A BR PI0507544 A BRPI0507544 A BR PI0507544A
Authority
BR
Brazil
Prior art keywords
treatment
corticosteroids
beta
combination
respiratory diseases
Prior art date
Application number
BRPI0507544-0A
Other languages
English (en)
Inventor
Robin Alec Fairhurst
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0507544A publication Critical patent/BRPI0507544A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

COMBINAçãO DE AGONISTAS DE BENZOTIAZOL-2-ONA BETA-2 ADRENORECEPTORES E CORTICOSTERóIDES PARA O TRATAMENTO DE DOENçAS RESPIRATóRIAS. A presente invenção refere-se a um medicamentocompreendendo,separadamente ou juntos, (A) um composto de fórmula (I)em forma livre ou de sal ou de solvato, em que X tem o significado conforme indicado na especificação ; e (B) um corticosteroide , para administração simultanea, sequencial ou separada no tratamento de uma doença inflamatória obstrutiva as vias aereas, a proporção molar de (A) para (B) sendo de 100:1 a 1:300.
BRPI0507544-0A 2004-02-09 2005-02-08 combinação de agonistas de benzotiazol-2-ona beta-2 adrenoreceptores e corticosteróides para o tratamento de doenças respiratórias BRPI0507544A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0402797.5A GB0402797D0 (en) 2004-02-09 2004-02-09 Organic compounds
PCT/EP2005/001241 WO2005074924A1 (en) 2004-02-09 2005-02-08 Combination of benzothiazol-2-one beta2 adrenoceptor agonists and corticosteroids for the treatment of respiratory diseases

Publications (1)

Publication Number Publication Date
BRPI0507544A true BRPI0507544A (pt) 2007-06-12

Family

ID=31985893

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507544-0A BRPI0507544A (pt) 2004-02-09 2005-02-08 combinação de agonistas de benzotiazol-2-ona beta-2 adrenoreceptores e corticosteróides para o tratamento de doenças respiratórias

Country Status (13)

Country Link
EP (1) EP1715860A1 (pt)
JP (1) JP2007522141A (pt)
KR (1) KR20060127974A (pt)
CN (1) CN1917875A (pt)
AR (1) AR047962A1 (pt)
AU (1) AU2005210140A1 (pt)
BR (1) BRPI0507544A (pt)
CA (1) CA2552938A1 (pt)
GB (1) GB0402797D0 (pt)
PE (1) PE20050692A1 (pt)
RU (1) RU2006132195A (pt)
TW (1) TW200536533A (pt)
WO (1) WO2005074924A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200738658A (en) 2005-08-09 2007-10-16 Astrazeneca Ab Novel compounds
TW200738659A (en) * 2005-08-29 2007-10-16 Astrazeneca Ab Novel compounds
TW200740781A (en) * 2005-08-29 2007-11-01 Astrazeneca Ab Novel compounds
JP5257073B2 (ja) * 2005-11-10 2013-08-07 ボーダー、ニコラス・エス ソフト型抗コリン作動性エステル
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
TW200745067A (en) * 2006-03-14 2007-12-16 Astrazeneca Ab Novel compounds
TW200833670A (en) 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
GB0702458D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab Salts 668
GB0702456D0 (en) * 2007-02-08 2007-03-21 Astrazeneca Ab New combination
EP2011534A1 (en) * 2007-07-03 2009-01-07 CHIESI FARMACEUTICI S.p.A. Metered dose inhaler actuator
CN101878221B (zh) 2007-11-30 2014-04-02 辉瑞有限公司 糖皮质激素受体激动剂
EP2534957B1 (en) 2007-12-14 2015-05-27 AeroDesigns, Inc Delivering aerosolizable products
WO2009087224A1 (en) 2008-01-11 2009-07-16 Novartis Ag Pyrimidines as kinase inhibitors
WO2009154557A1 (en) 2008-06-18 2009-12-23 Astrazeneca Ab Benzoxazinone derivatives acting as beta2-adrenoreceptor agonist for the treatment of respiratory disorders
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
GB201016912D0 (en) 2010-10-07 2010-11-24 Astrazeneca Ab Novel combination
MA34969B1 (fr) 2011-02-25 2014-03-01 Irm Llc Composes et compositions en tant qu inibiteurs de trk
JO3192B1 (ar) * 2011-09-06 2018-03-08 Novartis Ag مركب بنزوثيازولون
KR20220119529A (ko) 2016-06-02 2022-08-29 애브비 인코포레이티드 글루코코르티코이드 수용체 작용제 및 이의 면역접합체
WO2019106609A1 (en) 2017-12-01 2019-06-06 Abbvie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999009018A1 (fr) * 1997-08-14 1999-02-25 Kirin Beer Kabushiki Kaisha DERIVES DE BENZOTHIAZOLONE PRESENTANT UNE ACTIVITE SELECTIVE D'AGONISTE DU RECEPTEUR β2
PE20050130A1 (es) * 2002-08-09 2005-03-29 Novartis Ag Compuestos organicos

Also Published As

Publication number Publication date
AR047962A1 (es) 2006-03-15
WO2005074924A1 (en) 2005-08-18
PE20050692A1 (es) 2005-11-15
KR20060127974A (ko) 2006-12-13
EP1715860A1 (en) 2006-11-02
RU2006132195A (ru) 2008-03-20
AU2005210140A1 (en) 2005-08-18
CN1917875A (zh) 2007-02-21
CA2552938A1 (en) 2005-08-18
TW200536533A (en) 2005-11-16
GB0402797D0 (en) 2004-03-10
JP2007522141A (ja) 2007-08-09

Similar Documents

Publication Publication Date Title
BRPI0507544A (pt) combinação de agonistas de benzotiazol-2-ona beta-2 adrenoreceptores e corticosteróides para o tratamento de doenças respiratórias
BRPI0511327A (pt) combinações de glicopirrolato e agonistas do adrenorreceptor beta2
BRPI0115910B8 (pt) medicamento compreendendo 5-[(r)-2-(5,6-dietil-indan-2ilamino)-1-hidróxi-etil]-8-hidróxi-1h-quinolin-2-ona e corticóides para o tratamento de doencas inflamatórias ou obstrutivas das vias aéreas
BRPI0606736A2 (pt) combinação de compostos e esteróides de metilxantina para tratar doenças respiratórias crÈnicas
WO2007143607A3 (en) Method of treating atrophic vaginitis
BRPI0507966A (pt) uso de meloxicam para o tratamento de doenças respiratórias em porcos
NZ631024A (en) Therapies for hematologic malignancies
BR112014008789A2 (pt) prevenção e tratamento de condições oculares
HK1104471A1 (en) Opioids for the treatment of the chronic obstructive pulmonary disease (copd)
BR0209992A (pt) Inibidor de pde4 e um agente anticolinérgico em combinação para o tratamento de doenças obstrutivas das vias respiratórias
BR112013028095A2 (pt) inibidores de csf-1r para o tratamento de tumores cerebrais
BR112015020600A2 (pt) composição farmacêutica, método para o tratamento de e/ou melhorar doenças de gordura no fígado de origem não alcoólica e uso da composição
SI2150530T1 (sl) Substituirani sulfonamidni derivati
MX2008016134A (es) Derivados de fenol para el tratamiento de enfermedades respiratorias.
UA98136C2 (ru) Применение аклидиния для лечения респираторных заболеваний
BRPI0507657A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para tratar um distúrbio, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo
CY1108900T1 (el) Πολυθειωμενα γλυκοζιδια και αλατα αυτων
BRPI0518231A2 (pt) derivados de 2-amido-4-feniltiazol, o respectivo preparo e a respectiva aplicaÇço em terapÊutica
BR112012018765A2 (pt) agente profilático ou terapêutico para as doenças do trato biliar
BRPI0607258A2 (pt) uso, composto, bem como formulações farmacêuticas
ATE495159T1 (de) Diaminocyclohexan- und diaminocyclopentanderivate
BR112012020377A8 (pt) utilização de um ou mais selecionado do grupo constituído por um composto da fórmula (i), uma mistura racêmica-diastereomérica e um isômero óptico do referido composto, e um sal farmaceuticamente aceitável e uma pródroga do mesmo, método, composição farmacêutica e kit para tratamento de caquexia e embalagem comercial
BR112015009504A2 (pt) inibidores de rock
BRPI0606750A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, e,composição farmacêutica
BRPI0410707A (pt) composição que compreende antagonistas de receptores de progesterona e antiestrogênios puros para a profilaxia e tratamento de doenças dependentes de hormÈnios

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A E 6A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2099 DE 29/03/2011.